Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Comparision between A M Febcon and ANG Lifesciences IPO.
A M Febcon is a SME Fixed Price Issue IPO proposed to list at BSE SME while ANG Lifesciences IPO is a SME Fixed Price Issue proposed to list at BSE SME.
| A M Febcon | ANG Lifesciences IPO | |
|---|---|---|
| Logo |  |
 |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Fixed Price Issue | Fixed Price Issue |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Gretex Corporate Services Limited | Guiness Corporate Advisors Pvt Ltd |
| Registrar | Kfin Technologies Limited | Bigshare Services Pvt Ltd |
| Market Maker | ||
| DRHP | ||
| RHP | RHP  |
|
| Anchor Investor | ||
| IPO Allotment URL |
The total issue size of A M Febcon is up to ₹6.68 Cr whereas the issue size of the ANG Lifesciences IPO is up to ₹12.01 Cr. The final issue price of A M Febcon is ₹18.00 per share and of ANG Lifesciences IPO is ₹80.00 per share.
| A M Febcon | ANG Lifesciences IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ₹18.00 per share | ₹80.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 8000 shares | 1600 shares |
| Fresh Issue Size | ||
| Fresh Issue Size (Amount) | ||
| OFS Issue Size | ||
| OFS Issue Size (Amount) | ||
| Issue Size Total | 37,12,000 shares | 15,00,800 shares |
| Issue Size Total (Amount) | up to ₹6.68 Cr | up to ₹12.01 Cr |
A M Febcon opens on Sep 01, 2017, while ANG Lifesciences IPO opens on Aug 29, 2017. The closing date of A M Febcon and ANG Lifesciences IPO is Sep 06, 2017, and Aug 31, 2017, respectively.
| A M Febcon | ANG Lifesciences IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Sep 01, 2017 | Aug 29, 2017 |
| Issue Close | Sep 06, 2017 | Aug 31, 2017 |
| Basis Of Allotment (Tentative) | ||
| Initiation of Refunds (Tentative) | ||
| Credit of Share (Tentative) | ||
| Listing date (Tentative) | ||
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
A M Febcon P/E ratio is , as compared to ANG Lifesciences IPO P/E ratio of .
| A M Febcon | ANG Lifesciences IPO | |
|---|---|---|
| Financial | ||
| Promoter Shareholding (Pre-Issue) | ||
| Promoter Shareholding (Post-Issue) | ||
| P/E Ratio | ||
| Market Cap | ||
| ROE | ||
| ROCE | ||
| Debt/Equity | ||
| EPS | ||
| RoNW |
In the A M Febcon retail investors (RII) are offered 18,56,000 shares while in ANG Lifesciences IPO retail investors are offered 18,56,000 shares. Qualified institutional buyers (QIB) are offered 0 shares in A M Febcon and 0 shares in ANG Lifesciences IPO.
| A M Febcon | ANG Lifesciences IPO | |
|---|---|---|
| Anchor Investor Reserveration | ||
| Market Maker Reserveration | ||
| QIB | 0 shares | 0 shares |
| NII | 18,56,000 shares | 7,12,000 shares |
| RII | 18,56,000 shares | 7,12,000 shares |
| Employee | ||
| Others | ||
| Total | 37,12,000 shares | 14,24,000 shares |
A M Febcon subscribed in total, whereas ANG Lifesciences IPO subscribed .
| A M Febcon | ANG Lifesciences IPO | |
|---|---|---|
| QIB (times) | ||
| NII (times) | ||
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | ||
| Employee (times) | ||
| Other (times) | ||
| Total (times) |
Add a public comment...
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
